AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24309956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising mimecan levels
Number of subjects: 142
Study 24309981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation and cediranib
Number of subjects: 40
Study 24309981 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation only (Control)
Number of subjects: 40
Study 24311016 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal reassurance by dental staff
Number of subjects: 270
Study 24311016 — intervention group
Group type: COMPARATOR
Intervention: No verbal reassurance (implied control)
Number of subjects: 270
Study 24311231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (DCE-CT)
Number of subjects: 23
Study 24311296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 80
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: High food reinforcement (PMAXHED)
Number of subjects: 199
Study 24311480 — intervention group
Group type: COMPARATOR
Intervention: Low food reinforcement (PMAXLED)
Number of subjects: 199
Study 24311480 — intervention group
Group type: COMPARATOR
Intervention: Low delay discounting (DD)
Number of subjects: 199
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: High delay discounting (DD10 and DD100)
Number of subjects: 199
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of PMAXLED × DD10
Number of subjects: 199
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of PMAXHED × DD10
Number of subjects: 199
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of PMAXHED × DD100
Number of subjects: 199
Study 24311480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of PMAXLED × DD100
Number of subjects: 199
Study 24311637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg starting dose, maintenance dose between 12.5 mg and 50 mg depending on tolerability
Number of subjects: 40
Study 24311637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 40
Study 24311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 concentrations
Number of subjects: 464
Study 24311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 levels
Number of subjects: 464
Study 24311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels
Number of subjects: 464
Study 24311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,25-dihyroxyvitamin D concentrations
Number of subjects: 464
Study 24311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary hyperparathyroidism
Number of subjects: 464
Study 24311743 — intervention group
Group type: EXPERIMENTAL
Intervention: Training rehabilitation professionals in communication and motivation skills
Number of subjects: 0
Study 24313609 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors' analysis of risk factors for cranial CT necessity
Number of subjects: 12876
Study 24313609 — intervention group
Group type: COMPARATOR
Intervention: Canadian CT Head Rule (CCHR)
Number of subjects: 12876
Study 24314209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic based prototype test
Number of subjects: 5000
Study 24314209 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic based prototype test
Number of subjects: 5000
Study 24314292 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0
Study 24314292 — intervention group
Group type: COMPARATOR
Intervention: RARα antagonist Ro415253
Number of subjects: 0
Study 24314307 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC)
Number of subjects: 49
Study 24314307 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with docetaxel (SD)
Number of subjects: 49
Study 24314307 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 49
Study 24314346 — intervention group
Group type: EXPERIMENTAL
Intervention: G-allele carriers
Number of subjects: 81
Study 24314346 — intervention group
Group type: COMPARATOR
Intervention: AA-homozygotes
Number of subjects: 81
Study 24315482 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct DDMFs
Number of subjects: 24
Study 24315482 — intervention group
Group type: COMPARATOR
Intervention: Reversed DDMFs
Number of subjects: 24
Study 24315482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 24315509 — intervention group
Group type: EXPERIMENTAL
Intervention: % trunk fat
Number of subjects: 391
Study 24315509 — intervention group
Group type: EXPERIMENTAL
Intervention: % leg fat
Number of subjects: 391
Study 24315509 — intervention group
Group type: EXPERIMENTAL
Intervention: % arm fat
Number of subjects: 391
Study 24315990 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin (9-39) (Ex-9)
Number of subjects: 24
Study 24315990 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 24
Study 24316314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation (FPP) 6g/day for 14 weeks
Number of subjects: 0
Study 24316314 — intervention group
Group type: COMPARATOR
Intervention: In vitro free radical scavenging activities of FPP
Number of subjects: 0
Study 24317406 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (3 weeks of text messages)
Number of subjects: 31
Study 24317406 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 31
Study 24318487 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition measured by dual energy X-ray absorptiometry
Number of subjects: 776
Study 24319018 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechemotherapy assessment of serum AMH
Number of subjects: 27
Study 24319018 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable serum AMH concentration at chemotherapy initiation
Number of subjects: 27
Study 24319462 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis using saline and sodium hyaluronate injections
Number of subjects: 30
Study 24319489 — intervention group
Group type: EXPERIMENTAL
Intervention: Caraway extract (CE) 30 mL/day
Number of subjects: 70
Study 24319489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24320967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mucosal potentially malignant diseases (PMD) management
Number of subjects: 0
Study 24321536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal group (actively progressing through puberty, n = 16)
Number of subjects: 41
Study 24321536 — intervention group
Group type: COMPARATOR
Intervention: Peripubertal group (n = 25)
Number of subjects: 41
Study 24321536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal group (actively progressing through puberty)
Number of subjects: 41
Study 24321701 — intervention group
Group type: EXPERIMENTAL
Intervention: The Food Friends nutrition intervention (12 weeks) and physical activity intervention (18 weeks) during preschool.
Number of subjects: 0
Study 24321701 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 sites)
Number of subjects: 0
Study 24321742 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda consumption
Number of subjects: 128
Study 24321746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of third party bone marrow-derived mesenchymal stromal cells (MSC)
Number of subjects: 40
Study 24321803 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC scale
Number of subjects: 4484
Study 24321803 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ
Number of subjects: 4484
Study 24321803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function only
Number of subjects: 4484
Study 24321803 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exacerbation history only
Number of subjects: 4484
Study 24321803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lung function and previous exacerbation history
Number of subjects: 4484
Study 24322398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 5640
Study 24322398 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 5640
Study 24322398 — intervention group
Group type: COMPARATOR
Intervention: β Blockers
Number of subjects: 5640
Study 24322398 — intervention group
Group type: COMPARATOR
Intervention: Calcium Channel Blockers
Number of subjects: 5640
Study 24322571 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI measured immediately before tracheal extubation
Number of subjects: 200
Study 24322571 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI threshold <50
Number of subjects: 200
Study 24323026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (200 mg) + Temsirolimus (25 mg)
Number of subjects: 60
Study 24323026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (160 mg) + Temsirolimus (50 mg)
Number of subjects: 60
Study 24323026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib + Temsirolimus
Number of subjects: 60
Study 24323468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 gram infused over 30 min
Number of subjects: 8
Study 24323468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem dosing regimens: 500 mg once daily, 750 mg once daily, 500 mg twice daily, and 1,000 mg once daily
Number of subjects: 8
Study 24323708 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) in the subacute phase (2-4 weeks after aSAH)
Number of subjects: 108
Study 24323708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation of functional outcomes in the chronic phase (1 year after aSAH)
Number of subjects: 108
Study 24323994 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault-injured youth
Number of subjects: 925
Study 24323994 — intervention group
Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 925
Study 24324590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg, every other day for 12 weeks
Number of subjects: 14
Study 24325689 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-F-compatible materials (self-expanding nitinol stents: Astron Pulsar or Pulsar-18 stent)
Number of subjects: 120
Study 24325691 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC self-expanding nitinol stent
Number of subjects: 100
Study 24326155 — intervention group
Group type: EXPERIMENTAL
Intervention: Full conditioning (FC)
Number of subjects: 44
Study 24326155 — intervention group
Group type: COMPARATOR
Intervention: Control (standard laparoscopy)
Number of subjects: 44
Study 24326304 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation
Number of subjects: 1025
Study 24326304 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation in participants aged 50 years or older
Number of subjects: 1025
Study 24327334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus everolimus
Number of subjects: 31
Study 24328387 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND AP (LBAP) system
Number of subjects: 57
Study 24328387 — intervention group
Group type: COMPARATOR
Intervention: Control (patients without OSA at baseline)
Number of subjects: 57
Study 24328415 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND AP laparoscopic adjustable gastric band (LAGB)
Number of subjects: 1620
Study 24328727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (28% fat, 12% MUFA)
Number of subjects: 475
Study 24328727 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (35% fat, 22% MUFA)
Number of subjects: 475
Study 24329107 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous epidermal sheets generated from ex vivo gene-corrected keratinocyte stem cells
Number of subjects: 0
Study 24329122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress
Number of subjects: 19
Study 24329122 — intervention group
Group type: COMPARATOR
Intervention: Control (matched controls)
Number of subjects: 19
Study 24329524 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing metformin
Number of subjects: 17374
Study 24329524 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing thiazolidinediones
Number of subjects: 17374
Study 24329524 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing DPP-IV inhibitors
Number of subjects: 17374
Study 24329524 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing sulphonylureas
Number of subjects: 17374
Study 24329524 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing glinides
Number of subjects: 17374
Study 24329524 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing thiazolidinediones
Number of subjects: 17374
Study 24329524 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing DPP-IV inhibitors
Number of subjects: 17374
Study 24329524 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 17374
Study 24329937 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin
Number of subjects: 2109
Study 24330256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low gut microbiota diversity during the first month of life
Number of subjects: 47
Study 24330256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low gut microbiota diversity during the first week of life
Number of subjects: 47
Study 24330256 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-associated eczema in infancy
Number of subjects: 47
Study 24330256 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota diversity at 12 months of age
Number of subjects: 47
Study 24330256 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota diversity
Number of subjects: 47
Study 24330333 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated AHA-LT VI plaques in cryptogenic stroke patients ipsilateral to the ischemic stroke
Number of subjects: 300
Study 24330333 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-LT VI plaques
Number of subjects: 300
Study 24330333 — intervention group
Group type: EXPERIMENTAL
Intervention: New ischemic lesions on cerebral MRI (including clinically silent lesions)
Number of subjects: 300
Study 24330333 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific AHA-LT VI plaque features
Number of subjects: 300
Study 24330446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 33
Study 24330454 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 210
Study 24330454 — intervention group
Group type: COMPARATOR
Intervention: Prudent dietary pattern
Number of subjects: 210
Study 24330470 — intervention group
Group type: EXPERIMENTAL
Intervention: PCRM-CI intervention group
Number of subjects: 149
Study 24330470 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 149
Study 24330670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ATP supplementation (400 mg per day)
Number of subjects: 0
Study 24330670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24330868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg/day)
Number of subjects: 148
Study 24331202 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCM patients (n=13)
Number of subjects: 13
Study 24331859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent reproductive coercion (RC)
Number of subjects: 3539
Study 24331859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to recent RC
Number of subjects: 3539
Study 24331859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to recent RC with history of IPV
Number of subjects: 3539
Study 24331859 — intervention group
Group type: EXPERIMENTAL
Intervention: History of IPV without recent RC
Number of subjects: 3539
Study 24332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 87
Study 24332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 87
Study 24332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 87
Study 24332189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein (HDL)
Number of subjects: 87
Study 24332189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione-S-transferase α3
Number of subjects: 87
Study 24332215 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Number of subjects: 7
Study 24332241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Number of subjects: 31
Study 24332409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 54
Study 24332418 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-derived fractional flow reserve (FFRct) before intervention
Number of subjects: 44
Study 24332418 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-derived fractional flow reserve (FFRct) after virtual stenting
Number of subjects: 44
Study 24332418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of FFRct to predict ischemia (FFR ≤ 0.8) prior to stenting
Number of subjects: 44
Study 24332418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of FFRct to predict ischemia (FFR ≤ 0.8) after stenting
Number of subjects: 44
Study 24332512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidilizumab (3 mg/kg IV every 4 weeks for four infusions, plus eight optional infusions every 4 weeks) + Rituximab (375 mg/m² IV weekly for 4 weeks starting 17 days after first pidilizumab infusion)
Number of subjects: 32
Study 24333321 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to increase fluid intake in residential care homes, including identifying and overcoming barriers to drinking.
Number of subjects: 0
Study 24333321 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24333512 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening colonoscopies
Number of subjects: 7215
Study 24334153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE)
Number of subjects: 0
Study 24334153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nosocomial RVGE
Number of subjects: 0
Study 24334158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with low-molecular-weight heparin or factor Xa-inhibitors only during hospitalisation when LOS ≤5 days.
Number of subjects: 4924
Study 24334159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continence education and self-management (17 clusters, 61 women)
Number of subjects: 259
Study 24334159 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence education (20 clusters, 64 women)
Number of subjects: 259
Study 24334159 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based self-management (17 clusters, 70 women)
Number of subjects: 259
Study 24334159 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (educational workshop on memory loss, polypharmacy and osteoporosis) (17 clusters, 64 women)
Number of subjects: 259
Study 24334159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention vs Control
Number of subjects: 259
Study 24334175 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 weeks in T1D-H group
Number of subjects: 40
Study 24334175 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 weeks in T1D-N group
Number of subjects: 40
Study 24334175 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin in both groups
Number of subjects: 40
Study 24334294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + Anagrelide
Number of subjects: 347
Study 24335103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 32
Study 24335156 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-leg X-ray
Number of subjects: 31
Study 24335156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination using the Mikulicz line
Number of subjects: 31
Study 24335249 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin therapy
Number of subjects: 0
Study 24335249 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug-monitoring scenario
Number of subjects: 0
Study 24335249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing model
Number of subjects: 0
Study 24335413 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rotation more than 45° (left or right) during surgery
Number of subjects: 52
Study 24335413 — intervention group
Group type: EXPERIMENTAL
Intervention: Head lift from head support
Number of subjects: 52
Study 24335442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care emergency surgery
Number of subjects: 6098
Study 24335498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesin complex mutations
Number of subjects: 389
Study 24335595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and radiotherapy (cetux-RT) added to perioperative chemotherapy (ECX)
Number of subjects: 12
Study 24335595 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (ECX)
Number of subjects: 12
Study 24335630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 50
Study 24335630 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful union
Number of subjects: 50
Study 24335630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonunion patients
Number of subjects: 50
Study 24335630 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index and SF-36 version 2
Number of subjects: 50
Study 24335884 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 803
Study 24337621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2-3), Ramosetron (0.6 mg on day 1), Dexamethasone (20 mg on day 1)
Number of subjects: 89
Study 24337621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant, Ramosetron, Dexamethasone
Number of subjects: 89
Study 24338498 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors)
Number of subjects: 32
Study 24338498 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation criteria based on tumor size (RECIST)
Number of subjects: 32